Patient P-01692
Therapy response
Improving
Tolerance
Improving
GI state
Unstable
Inflammatory state
Improving
Nutritional resilience
Unstable
Discontinuation risk
91%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −21% vs expected — Dietary Support Protocol NP-02
- Day 48 Tolerance state changed — Unstable → Improving
- Day 50 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 50 GI-04 recommended — GI Support Protocol GI-04
- Day 51 Patient declined — Not now
- Day 69 ME-01 recommended — Monitoring Escalation ME-01
- Day 70 Patient accepted — Started ME-01 in the companion
- Day 73 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 50.
Primary contributors, last 14 days
- Inflammatory activity-9
- Nutritional resilience+8
- Treatment adherence+5
- Toxicity-4
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −21%
- GI Support Protocol GI-04Day 50Declined by patient
- Monitoring Escalation ME-01Day 69Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 55
- WearableHRV 23 ms, trending down
- Autonomic recovery ↑65
- WearableResting HR 75 bpm
- Wearable1,907 steps/day
- WearableShort sleep window
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 64 and rising
- WearableSleep 5.4 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 30/100
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑20
- BloodToxicity index 44
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.8 · butyrate capacity 30/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 23 ms
- Sleep
- 6.0 h
- Steps
- 2,604
- Resting HR
- 74 bpm
Daily log: GI score 64, nutritional resilience 38, adherence 47.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01462 | 65% | S14 | NP-02 | improved | 47 |
| P-01496 | 64% | S14 | SC-12 | improved | 46 |
| P-01393 | 60% | S14 | GI-04 | improved | 53 |
| P-01872 | 59% | S14 | NP-02 | improved | 47 |
| P-01865 | 58% | S14 | NP-02 | no change | 51 |
| P-01879 | 56% | S14 | SC-12 | improved | 51 |
| P-01433 | 55% | S14 | GI-04 | improved | 48 |
| P-01482 | 54% | S14 | GI-04 | improved | 47 |
| P-01614 | 54% | S14 | GI-04 | improved | 53 |
| P-01364 | 53% | S14 | GI-04 | improved | 49 |
| P-01406 | 53% | S18 | GI-04 | improved | 50 |
| P-01332 | 52% | S14 | NP-02 | improved | 43 |